Anemia treatment and left ventricular hypertrophy in non-dialysis chronic kidney disease
Robert N. Foley
Peter A. McCullough
摘要： To this day, the target hemoglobin level that minimizes cardiovascular risk in chronic kidney disease (CKD) patients remains unclear. When one examines the many randomized trials of epoetin therapy in aggregate, enhanced quality of life provides the most cogent argument for hemoglobin levels above 110 g/L. It remains unclear whether treatment of anemia improves longevity, or even a surrogate marker (such as left ventricular [LV] mass index), especially when applied at earlier phases of CKD.
机标关键词：
分类号：R6(外科学)
论文发表日期：2005-10-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：1( 195 )